Post-earnings recap
Reported
Wed, Aug 7, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a narrower loss than expected, which contributed to a positive stock reaction, with shares rising 3.85%. The company did not disclose revenue figures, but management's optimistic tone suggests confidence in their ongoing projects and future potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.84 | N/A | +21.45% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance despite not providing specific revenue figures. They emphasized their commitment to pipeline development.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.